Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids

Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids

Source: 
Benzinga
snippet: 

Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc (NYSE: PFE) have announced positive data from the Phase 3 LIBERTY randomized withdrawal study evaluating relugolix combination therapy in women with uterine fibroids.